ReviewFrontiers in immunology2026
Microfluidic engineering of immune-competent organs-on-chips and their applications.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Precision microbiome medicine and therapeutics: the enabling role of in vitro gut models.FEMS microbiology reviews · 2026Review
- Microfluidic chips for decoding cancer-immune crosstalk in immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emerging field of biomimetic microfluidics is advancing the engineering of immune-competent Organs-on-Chips. These systems overcome the constraints of conventional models by using precise microengineering to regulate cellular composition, three-dimensional extracellular matrix architecture, and dynamic biophysical signals. This review summarizes the core design principles, integrating microfluidics, tissue engineering, and biomaterials, that facilitate the reconstitution of physiological and immune-relevant pathological niches. We examine how such tunable control is utilized to model specific immune contexts, including tumor microenvironments for immunotherapy screening, inflammatory processes in barrier organs, and autoimmune disorders. The integration of these chips with patient-derived organoids and multi-omics technologies is emphasized, illustrating how this combined approach provides new mechanistic insights into human immunology. Finally, we consider the translational prospects of these platforms in promoting personalized immuno-medicine and accelerating immunotherapeutic development, while also addressing ongoing challenges in standardization and the incorporation of greater biological complexity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.